Form 4: MLYS CMO Sells Shares Under 10b5-1 Plan

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed a pre-planned sale of 416 common shares following an option exercise.

Summary

• Chief Medical Officer David Malcom Rodman engaged in transactions involving Mineralys Therapeutics, Inc. common stock.
• On January 20, 2026, Rodman acquired 416 shares of common stock at an exercise price of $15.44 per share through a stock option exercise.
• Concurrently, on January 20, 2026, Rodman disposed of 416 shares of common stock at a price of $32.10 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on October 6, 2025.
• Following these transactions, Rodman beneficially owns 50,437 shares of common stock and 5,834 derivative securities (stock options).
• The stock option exercised vested 25% on the first anniversary of the grant date, with the remainder vesting in 36 substantially equal monthly installments, and has an expiration date of March 17, 2033.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine, pre-planned insider transaction (option exercise and sale) which is common for executives managing their equity compensation. The sale is profitable for the insider, but it's a small percentage of their total holdings and executed under a 10b5-1 plan, so it doesn't signal strong positive or negative sentiment about the company's future prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The sale price of $32.10 per share is significantly higher than the option exercise price of $15.44, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction and does not directly relate to broader industry trends or competitors, other than reflecting the compensation structure common in the biotech/pharma industry.

Stakeholder Impact

• Shareholders: The sale by a Chief Medical Officer could be viewed with slight caution, but its pre-planned nature under Rule 10b5-1 mitigates concerns about immediate negative sentiment. The amount sold is relatively small compared to total holdings.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction by the Chief Medical Officer, involving the exercise of stock options and a subsequent sale of a portion of the shares. The transaction was executed under a Rule 10b5-1 plan, which suggests it's part of a personal financial management strategy rather than a reaction to new material information. While an insider sale reduces direct equity exposure, the amount is relatively small, and the pre-planned nature typically lessens any negative market interpretation. There is no new fundamental information about the company's operations, financial health, or strategic direction in this filing to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Option Exercise, Rule 10b5-1, Chief Medical Officer, David Malcom Rodman, Equity Sale